Background {#Sec1}
==========

Acute respiratory distress syndrome (ARDS) is a heterogeneous syndrome with complex pathophysiologic mechanisms and has a high mortality rate up to 45% in severe ARDS \[[@CR1]\]. A lung-protective ventilation strategy with lower tidal volume remains the cornerstone of treatment for ARDS and is associated with improved survival \[[@CR2]\]. Many alternative rescue treatments had been investigated for ARDS with severe hypoxemia, but their impact on mortality is undetermined, except for early application of prolonged prone position \[[@CR3]\].

Although the survival benefit is not well established, extracorporeal membrane oxygenation (ECMO) may be a salvage therapy for severe ARDS patients with profound hypoxemia refractory to conventional mechanical ventilation \[[@CR4]--[@CR6]\]. For severe ARDS patients receiving ECMO support, the positive result of a multicenter randomized controlled trial \[[@CR7]\], favorable outcomes during the 2009 influenza A (H1N1) pandemic \[[@CR8]\] and major advances in technology with less complication had allowed ECMO widespread application over the past decade \[[@CR5], [@CR9], [@CR10]\]. However, the precise indications, optimal timing to initiate and factors associated with mortality for severe ARDS patients who received ECMO were still not well established \[[@CR4], [@CR6], [@CR9], [@CR11]\].

ECMO facilitates an ultra-protective ventilation of more lowering delivered tidal volume and airway pressure for resting the lungs. This ultra-protective lung strategy ideally may improve outcomes by further minimizing ventilator-induced lung injury (VILI) \[[@CR4], [@CR6], [@CR11]--[@CR16]\]. Although ECMO support limited stress and strain with ultra-protective ventilation, the specific extent of lung rest strategy and the optimal mechanical ventilation settings targets during ECMO for severe ARDS patients remained uncertain \[[@CR11]--[@CR16]\]. There was no large multicenter prospective randomized controlled trial to address the optimal mechanical ventilation settings during ECMO in severe ARDS patients. In most clinical practice, the mechanical ventilation settings during the ECMO depended on the clinicians' experience \[[@CR6]\]. A recent study from 3562 patients with ARDS enrolled in 9 previous reported randomized controlled trials concluded that decreases in driving pressure were strongly associated with increased survival for patients with ARDS \[[@CR17]\]. However, it is uncertain whether a similar association between driving pressure and survival exists for severe ARDS patients receiving ECMO.

The aim of this study was to investigate the influences of clinical variables and mechanical ventilation settings on the survival outcomes for severe ARDS patients receiving ECMO.

Methods {#Sec2}
=======

Patient papulation {#Sec3}
------------------

This study was conducted in the medical and surgical ICUs at a tertiary care referral center, Chang Gung Memorial Hospital, with a 3700-bed general ward and a 278-bed adult ICU. The local Institutional Review Board for Human Research approved this study (CGMH IRB No. 201600632B0), and the need for informed consent was waived due to the retrospective nature of the study.

We analyzed severe ARDS patients who received ECMO for refractory hypoxemia between May 2006 and October 2015. Severe ARDS was defined by the Berlin definition with acute onset within 1 week, bilateral lungs opacities, no evidence of cardiac failure-related hydrostatic edema by echocardiography and PaO~2~/FiO~2~ ratio \<100 mmHg with positive end-expiratory pressure (PEEP) ≥5 cm H~2~O \[[@CR1]\]. Exclusion criteria were: (1) age \<20 years, (2) malignancies with poor prognosis within 5 years and (3) significant underlying comorbidities or severe multiple organ failure refractory to treatment (4) mortality within 24 h after ECMO initiation. Before consideration of ECMO initiation, all patients were sedated and ventilated with pressure-controlled ventilation using tidal volume of 6--8 ml/kg predicted body weight (PBW).

ECMO management and protocol {#Sec4}
----------------------------

The decision to initiate ECMO was made by treating intensive care specialist when persistent hypoxemia (PaO~2~/FiO~2~ ratio \<80 mmHg) at least 6 h, despite aggressive mechanical ventilation support (PEEP \> 10 cm H~2~O or peak inspiratory pressure \>35 cm H~2~O). All patients were deeply sedated and paralyzed with continuous neuromuscular blocking agent and ventilated with pressure-controlled ventilation until weaning attempt from ECMO. Initial mechanical ventilator settings protocol after ECMO support were as follows: tidal volume 4--6 ml/kg PBW; PEEP 10--15 cm H~2~O; peak inspiratory pressure 25--30 cm H~2~O; respiratory rate 10--12 breaths per minute; and FiO~2~ adjusted to maintain arterial oxygen saturation above 90%. The criteria for weaning from ECMO in our experience were resolving lungs infiltration, lung compliance \>20 ml/cm H~2~O, PaO~2~ \> 60 mmHg and PaCO~2~ \< 45 mmHg under FiO~2~ ≦ 0.4, PEEP ≦ 6--8 cm H~2~O, and peak inspiratory pressure ≦30 cm H~2~O.

Data collection {#Sec5}
---------------

The following data were collected from the hospital chart and analyzed: age, sex, body weight, body mass index, etiologies of ARDS, underlying diseases, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment (SOFA) score and lung injury score on the day of ICU admission.

Arterial blood gas, ARDS duration before ECMO, ventilator settings included tidal volume, respiratory rate, PEEP, peak inspiratory pressure, dynamic driving pressure (the difference between peak inspiratory pressure and PEEP) and FiO~2~ were recorded before ECMO initiation. After ECMO support, daily arterial blood gas, ventilator settings, ECMO settings (gas flow, blood flow and FiO~2~) and ECMO complications (oxygenator failure, blood clots in oxygenator or circuit, bleeding, infection or others) were recorded until ICU discharge.

Statistical analyses {#Sec6}
--------------------

Continuous variables were presented as means ± standard deviation or median (interquartile range), and categorical variables were reported as numbers (percentages). Student's *t* test or the Mann--Whitney *U* test was used to compare continuous variables between survivors and nonsurvivors, as appropriate. Categorical variables were tested using Chi-square test for equal proportion or Fisher's exact test. Risk factors associated with ICU mortality were analyzed using Cox proportional hazards regression model with stepwise selection procedure. All variables that were related to ICU mortality with a *p* \< 0.20 were finally introduced in the model. Calibration was assessed using Hosmer--Lemeshow goodness-of-fit test (C statistic, goodness of fit was defined as a *p* value \>0.05), and discrimination was assessed by the area under the receiver operating characteristics curve. Cutoff points were calculated by obtaining the best Youden index (sensitivity + specificity − 1). The results were presented as hazard ratio (HR) \[95% confidence interval (CI)\]. Cumulative survival curves as a function of time were generated using the Kaplan--Meier approach and compared using the log-rank test. All statistical analyses were performed with SPSS 21.0 statistical software. A *p* value \<0.05 was considered significant.

Results {#Sec7}
=======

During the study period, 2622 patients were admitted to our ICUs with a diagnosis of ARDS, of whom 165 patients with severe ARDS receiving ECMO were included. A total of 158 patients were finally analyzed (Fig. [1](#Fig1){ref-type="fig"}). The overall ICU survival rate was 44.9%.Fig. 1Flowchart of severe acute respiratory distress syndrome (ARDS) patients receiving extracorporeal membrane oxygenation (ECMO)

Details of the demographic data, clinical characteristics and ventilator settings before ECMO initiation between survivors and nonsurvivors are presented in Table [1](#Tab1){ref-type="table"}. The main cause of ARDS was bacterial pneumonia, followed by viral pneumonia. Survivors were younger and had less immunocompromised and lower baseline APACHE II, SOFA scores than nonsurvivors. The duration of ARDS before ECMO initiation was significantly shorter in survivors than nonsurvivors. Mechanical ventilation settings and other ventilation parameters before ECMO support in two groups did not show significantly difference. Venovenous ECMO was used for 120 patients (75.9%), and other 38 patients received venoarterial ECMO with 11 patients shifted to venovenous ECMO later. Venoarterial ECMO was performed for heart failure with intractable shock complicating ARDS-related diseases. The median duration of ECMO, ventilator, ICU and hospital stay were 9 (5--15), 20 (12--38), 23 (13--43) and 39 (21--64) days, respectively. Overall, 43 (27.2%) patients had one or more ECMO-related complications with 4 patients died due to intracranial hemorrhage.Table 1Characteristics of survivors and nonsurvivors of severe ARDS patients with ECMO supportCharacteristicAll patients (*n* = 158)Survivors (*n* = 71)Nonsurvivors (*n* = 87)*p* valueAge (years)50.3 ± 16.346.0 ± 16.553.8 ± 15.40.003Male (gender)108 (68.4%)48 (67.6%)60 (69%)0.855Body weight (kg)68.5 ± 16.770.1 ± 17.467.1 ± 16.10.268Body mass index (kg/m^2^)25.8 ± 5.226.0 ± 5.825.6 ± 4.70.656ARDS etiologies Bacterial pneumonia55 (34.8%)19 (26.8%)36 (41.4%)0.055 Viral pneumonia24 (15.2%)13 (18.3%)11(12.6%)0.327 Nonpulmonary sepsis21 (13.3%)4 (5.6%)17 (19.5%)0.017 Pulmonary contusion19 (12%)13 (18.3%)6 (6.9%)0.028 Aspiration pneumonia11 (7%)8 (11.3%)3 (3.4%)0.066 Other causes28 (17.7%)14 (19.7%)14 (16.1%)1.0Comorbidities Diabetes mellitus40 (25.3%)23 (32.4%)17 (19.5%)0.065 Cerebrovascular accident10 (6.3%)6 (8.5%)4 (4.6%)0.346 Chronic heart disease^a^55 (34.8%)23 (32.4%)32 (36.8%)0.565 Chronic lung disease^b^16 (10.1%)4 (5.6%)12 (13.8%)0.115 Chronic liver disease^c^22 (13.9%)6 (8.5%)16 (18.4%)0.073 Chronic kidney disease^d^18 (11.4%)8 (11.3%)10 (11.5%)0.964 Immunocompromised^e^42 (26.6%)11 (15.5%)31 (35.6%)0.004APACHE II score23.4 ± 7.521.8 ± 8.024.7 ± 6.90.014SOFA score10.9 ± 3.210.3 ± 3.111.4 ± 3.20.042Lung injury score3.37 ± 0.443.44 ± 0.433.32 ± 0.450.085ARDS duration before ECMO (h)28.0 (7.0--129.0)9.8 (3.7--64.0)54.0 (16.0--200.0)\<0.001Pre-ECMO ventilator settings PaO~2~/FiO~2~ (mmHg)64 (52--87)64 (53--80)63 (52--107)0.198 Tidal volume (ml/kg PBW)7.7 ± 2.47.7 ± 2.37.8 ± 2.40.753 PEEP (cm H~2~O)12.0 ± 2.812.2 ± 2.511.8 ± 3.00.319 Peak inspiratory pressure (cm H~2~O)33.9 ± 6.533.6 ± 6.034.1 ± 6.80.645 Mean airway pressure (cm H~2~O)18.7 ± 4.418.4 ± 4.218.9 ± 4.60.539 Dynamic driving pressure (cm H~2~O)21.9 ± 6.221.1 ± 5.822.6 ± 6.50.139 Dynamic compliance (ml/cm H~2~O)22.5 ± 11.223.4 ± 11.621.7 ± 10.90.366Pre-ECMO blood gas pH7.28 ± 0.147.27 ± 0.127.28 ± 0.150.842 PaCO~2~ (mmHg)52.2 ± 18.850.7 ± 19.653.5 ± 18.20.359 PaO~2~ (mmHg)73.3 ± 39.371.6 ± 39.274.8 ± 39.60.617 Saturation (%)84.4 ± 15.984.7 ± 12.784.1 ± 18.20.804Ventilator settings from day 1 to 3 on ECMO PaO~2~/FiO~2~ (mmHg)178 (131--240)200 (146--247)165 (124--212)0.588 Tidal volume (ml/kg PBW)6.0 ± 2.26.1 ± 2.06.0 ± 2.40.914 PEEP (cm H~2~O)12.0 ± 3.312.3 ± 3.211.7 ± 3.30.202 Peak inspiratory pressure (cm H~2~O)31.7 ± 5.630.6 ± 5.132.8 ± 5.90.018 Mean airway pressure (cm H~2~O)17.7 ± 4.017.4 ± 3.617.9 ± 4.30.406 Dynamic driving pressure (cm H~2~O)19.8 ± 6.318.3 ± 6.021.1 ± 6.40.006 Dynamic compliance (ml/cm H~2~O)19.2 ± 8.121.1 ± 7.717.4 ± 8.10.006Duration of ECMO (days)9.0 (4.8--14.6)8.7 (5.0--13.0)9.8 (4.7--16.1)0.696ECMO complications43 (27.2%)16 (22.5%)27 (31.0%)0.232Data are presented as mean ± standard deviation, count or median (interquartile range)*APACHE* Acute Physiology and Chronic Health Evaluation, *ARDS* acute respiratory distress syndrome, *ECMO* extracorporeal membrane oxygenation, *FiO* ~*2*~ fraction of inspired oxygen, *PaCO* ~*2*~ partial pressure of carbon dioxide in arterial blood, *PaO* ~*2*~ partial pressure of oxygen in arterial blood, *PBW* predicted body weight, *PEEP* positive end-expiratory pressure, *SOFA* Sequential Organ Failure Assessment. Dynamic driving pressure: (peak inspiratory pressure---PEEP)^a^Chronic heart disease included chronic heart failure, valvular heart disease, arrhythmia, hypertension and coronary artery disease^b^Chronic lung disease included chronic obstructive pulmonary disease, interstitial lung disease, tuberculosis and bronchiectasis^c^Chronic liver disease included chronic hepatitis and cirrhosis^d^Chronic kidney disease included chronic renal insufficiency with creatinine level above 1.5 mg/dl^e^Immunocompromised included hematological malignancies, solid tumors, sold organ transplantation, long-term steroid or immunosuppressant use and human immunodeficiency virus infection

Mechanical ventilator settings after ECMO support {#Sec8}
-------------------------------------------------

Daily arterial blood gas, mechanical ventilation settings were recorded, and we analyzed the data at 6 h, day 1, 2, 3 and 7 after ECMO initiation. After ECMO support, tidal volume was reduced, but did not reveal significantly difference between survivors and nonsurvivors until day 7. After ECMO support 6 h, survivors had significant higher PEEP level than nonsurvivors (12.6 ± 3.3 vs. 11.4 ± 3.1 cm H~2~O, *p* = 0.02), but there was no difference until day 7. Both peak inspiratory pressure and dynamic driving pressure were decreased after ECMO initiation. Nonsurvivors had significantly higher peak inspiratory pressure after ECMO support day 2, day 3 and day 7 (32.8 ± 6.4 vs. 30.6 ± 5.2 cm H~2~O, *p* = 0.02; 32.9 ± 6.8 vs. 30.4 ± 6.0 cm H~2~O, *p* = 0.02; 33.1 ± 7.1 vs. 29.8 ± 5.7 cm H~2~O, *p* = 0.01). Nonsurvivors also had significantly higher dynamic driving pressure after ECMO support until day 7 (all *p* \< 0.05) (Table [1](#Tab1){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Serial changes in **a** tidal volume, **b** positive end-expiratory pressure (PEEP), **c** peak inspiratory pressure and **d** dynamic driving pressure before and after extracorporeal membrane oxygenation (ECMO). *Error bars* represent the mean ± standard error. *Dark line* denotes survivors and *gray line* denotes nonsurvivors. \*A value of *p* less than 0.05 compared between survivors and nonsurvivors

Outcomes analysis {#Sec9}
-----------------

Cox proportional hazards regression model was used to identify variables that have prognostic value for ICU mortality (Table [2](#Tab2){ref-type="table"}). Immunocompromised status, APACHE II score, ARDS duration before ECMO and mean dynamic driving pressure from day 1 to 3 on ECMO remained independently associated with ICU mortality. Dynamic driving pressure with a cutoff point of 21 cm H~2~O exhibited the best Youden index, and mean dynamic driving pressure greater than 21 cm H~2~O from day 1 to 3 on ECMO was associated with higher mortality (HR 2.553; 95% CI 1.607--4.054; *p* \< 0.001; data not shown). Peak inspiratory pressure and SOFA score were not retained in the final model due to highly correlated with dynamic driving pressure and APACHE II score, respectively. Time to ECMO removal analysis and a landmark analysis excluding 7 patients who died in the first 24 h after ECMO revealed that severe ARDS patients with mean dynamic driving pressure ≦21 cm H~2~O had significantly higher rate of ECMO removal than those with mean dynamic driving pressure \>21 cm H~2~O from day 1 to 3 on ECMO (*p* = 0.017, log-rank test) (Fig. [3](#Fig3){ref-type="fig"}). The overall survival rate of severe ARDS patients with mean dynamic driving pressure ≦21 cm H~2~O was significantly higher than those with mean dynamic driving pressure \>21 cm H~2~O from day 1 to 3 on ECMO (56.1 vs. 33.3%, *p* = 0.001, log-rank test) (Fig. [4](#Fig4){ref-type="fig"}).Table 2Cox proportional hazards regression model with ICU mortality as outcomeFactorsHazard ratio (95% CI)*p* valueUnivariate analysis Age1.011 (0.998--1.025)0.108 Pulmonary contusion0.417 (0.181--0.958)0.039 Aspiration pneumonia0.405 (0.128--1.285)0.125 Diabetes mellitus0.635 (0.373--1.083)0.096 Chronic liver disease1.611 (0.931--2.788)0.088 Immunocompromised1.731 (1.115--2.689)0.015 APACHE II score1.032 (1.004--1.062)0.027 Lung injury score0.596 (0.374--0.951)0.030 ARDS duration before ECMO1.002 (1.001--1.003)0.001 Mean PEEP from day 1 to 3 on ECMO0.942 (0.877--1.013)0.106 Mean dynamic driving pressure from day 1 to 3 on ECMO1.052 (1.015--1.090)0.005 Mean dynamic compliance from day 1 to 3 on ECMO0.971 (0.941--1.002)0.069Multivariate analysis Immunocompromised1.957 (1.216--3.147)0.006 APACHE II score1.039 (1.005--1.073)0.023 ARDS duration before ECMO1.002 (1.000--1.003)0.029 Mean dynamic driving pressure from day 1 to 3 on ECMO1.070 (1.026--1.116)0.002*APACHE* Acute Physiology and Chronic Health Evaluation, *ARDS* acute respiratory distress syndrome, *CI* confidence interval, *ECMO* extracorporeal membrane oxygenation, *ICU* intensive care unit, *PEEP* positive end-expiratory pressure. Dynamic driving pressure: (peak inspiratory pressure---PEEP) Fig. 3Time to ECMO removal analysis in patients with severe acute respiratory distress syndrome (ARDS) on extracorporeal membrane oxygenation (ECMO). *Blue line* denotes patients with mean dynamic driving pressure ≦21 cm H~2~O, and *green line* denotes patients with mean dynamic driving pressure \>21 cm H~2~O from day 1 to 3 on ECMO (*p* = 0.017) Fig. 4Kaplan--Meier survival curves in patients with severe acute respiratory distress syndrome (ARDS) on extracorporeal membrane oxygenation (ECMO). *Blue line* denotes patients with mean dynamic driving pressure ≦21 cm H~2~O, and *green line* denotes patients with mean dynamic driving pressure \>21 cm H~2~O from day 1 to 3 on ECMO. The overall survival rate of patients with dynamic driving pressure ≦21 cm H~2~O was significantly higher than those with dynamic driving pressure \>21 cm H~2~O (56.1 vs. 33.3%, *p* = 0.001)

Discussion {#Sec10}
==========

Our study analyzed the serial ventilator settings changes in severe ARDS patients after ECMO support and found that increased dynamic driving pressure during the first 3 days was independently associated with higher mortality. In addition, immunocompromised status, APACHE II score and the duration of ARDS before ECMO initiation were also significantly associated with survival.

Amato and colleagues analyzed nine randomized controlled trials in ARDS patients and concluded that driving pressure was most strong predictor of mortality \[[@CR17]\]. Recent study also demonstrated decreased respiratory system and transpulmonary driving pressure were associated with improved 28-day mortality in ARDS patients \[[@CR18]\]. A prospective multicenter study in 15 moderate ARDS patients with low-flow extracorporeal carbon dioxide removal (ECCO~2~R) demonstrated that driving pressure was significantly reduced during the first two days compared to baseline \[[@CR19], [@CR20]\]. However, the role of driving pressure on the severe ARDS patients requiring ECMO was uncertain, and a clinical review recommended that driving pressure is important determinant of outcome during ECMO \[[@CR6]\]. The present study in severe ARDS patients receiving ECMO revealed that dynamic driving pressure from day 1 to 3 on ECMO was independently associated with mortality (Table [2](#Tab2){ref-type="table"}).

Driving pressure was inversely proportional to compliance of respiratory system and had two common definitions: the difference between plateau pressure and PEEP and the difference between peak inspiratory pressure and PEEP \[[@CR21]\]. There was no study compared different modes of ventilation during ECMO, and pressure-controlled mode appears to be advocated \[[@CR12]\]. With pressure-controlled ventilation, pressure is maintained constant throughout inspiration, and flow decreases during inspiration and is often followed by a period of zero flow at end inspiration. Peak inspiratory pressure and peak alveolar pressure (plateau pressure) may be equal during no flow status \[[@CR22]\]. Therefore, we used the difference between peak inspiratory pressure and PEEP as calculation of "dynamic" driving pressure. In fact, the most correct form can be obtained using transpulmonary driving pressure by esophageal manometry, but it is not easy to use in clinical practice. Reduction in dynamic driving pressure were found after ECMO initiation, and the values of survivors continued decreasing and exhibited significantly lower than nonsurvivors until day 7 (Fig. [2](#Fig2){ref-type="fig"}). Better lungs compliance and larger proportion of recovered functional lung size could have benefitted the survivors. Manipulation of driving pressure could be applied for ventilator management beside by adjusting the tidal volume and PEEP \[[@CR18]\]. Although standardized ventilation protocol for ARDS patients before and after ECMO was followed, it remains unclear from our observational study to definitely conclude that driving pressure was causally related to outcome or simply another marker for ARDS severity and it needed further randomized controlled trials to confirm our findings.

Although ECMO facilitates the use of lung-protective ventilation, the optimal mechanical ventilation management is unknown \[[@CR4], [@CR6], [@CR11]--[@CR14]\]. The lowering levels of plateau pressure and tidal volume have been related to decreased mortality \[[@CR16]\]. Therefore, an ultra-protective ventilation strategy with low tidal volume reduction (\<4 ml/kg, PBW), airway pressure reduction and adequate PEEP was suggested to mitigate further VILI \[[@CR4], [@CR11]--[@CR14]\]. Mechanical ventilation during ECMO may have an important impact on mortality. A cohort study of influenza A (H1N1)-induced ARDS patients receiving ECMO revealed that higher plateau pressure on the first day under ECMO was significantly associated with increased ICU mortality \[[@CR23]\]. Another retrospective study demonstrated that higher PEEP levels during the first 3 days on ECMO were independently associated with lower ICU mortality \[[@CR24]\]. A systemic review summarized ventilation practices in ARDS patients with ECMO, and mortality was lower among patients who had lower ventilation intensity following ECMO initiation \[[@CR14]\]. Our present study found that pre-ECMO ventilator settings exhibited no significant difference. After ECMO initiation, tidal volume, peak inspiratory pressure and dynamic driving pressure were all decreased, while PEEP levels were relative maintained. Dynamic driving pressure during first 3 days of ECMO support was independently related to ICU mortality. Whether these mechanical settings affected the outcome was not well known, and more information will be obtained from an ongoing study in the future (SOLVE ARDS: Strategies for Optimal Lung Ventilation in ECMO for ARDS; clinicaltrials.gov identifier NCT01990456).

Several studies had investigated the predictors of mortality for severe ARDS patients treated with ECMO \[[@CR10], [@CR23]--[@CR27]\]. Our study found that the duration of ARDS, APACHE II score and immunocompromised status before ECMO were independently associated with ICU mortality. The optimal timing for ECMO initiation had not been established, and mechanical ventilation may cause substantial VILI even under lung-protective strategy, which is worsened by delaying ECMO application for refractory hypoxemia \[[@CR4], [@CR13], [@CR26]--[@CR28]\]. Previous studies manifested duration of mechanical ventilation prior to ECMO support was correlated with mortality \[[@CR10], [@CR24]--[@CR27]\]. Our study found that survivors had significantly shorter ARDS duration before ECMO. Several studies reported that degree of systemic organ failure was correlated with outcome for ARDS patients before ECMO initiation \[[@CR6], [@CR24]--[@CR26], [@CR29], [@CR30]\], and we found that APACHE II score was significantly associated with ICU mortality. Furthermore, recent report included 2355 patients with severe ARDS receiving ECMO from multiple countries over a 13-year period concluded that immunocompromised status was independently associated with hospital survival \[[@CR10]\]. Immunocompromised status was independently associated with long-term outcomes form severe ARDS patients with ECMO \[[@CR25]\]. Our study also found that immunocompromised status was significantly related to ICU mortality.

There were several limitations of our study. First, this study is a retrospective analysis in one referral medical center, which may limit the generalization to other ICUs or hospitals. Besides, there might be residual and unmeasured confounding variables not included in our study and other biases during long period of study from 2006 to 2015 that could influence outcome. Second, APACHE II score was assessed only on the day of ICU admission and may not really reflect the dynamics of critical illness and treatment response. Serial evaluation of organ dysfunction during study period may be a better predictor of prognosis. Third, early application of prolonged prone position for severe ARDS patients as rescue therapy had survival benefit, but only a small number of our patients (*n* = 2) underwent prone position before ECMO. Finally, although ultra-protective ventilation strategy with ECMO based on a tidal volume reduction (\<4 ml/kg, PBW), our study showed relatively higher tidal volume (around 6 ml/kg, PBW) after ECMO support.

Conclusions {#Sec11}
===========

Our study found that immunocompromised status, APACHE II score and the duration of ARDS before ECMO initiation were significantly associated with ICU survival in severe ARDS patients with ECMO. Dynamic driving pressure during first 3 days of ECMO support was also independently related to ICU mortality. Further large multicenter, prospective randomized controlled trials are necessary to confirm the hypothesis that dynamic driving pressure could be a better predictor for survival in severe ARDS patients with ECMO support.

APACHE

:   Acute Physiology and Chronic Health Evaluation

ARDS

:   acute respiratory distress syndrome

CI

:   confidence interval

ECMO

:   extracorporeal membrane oxygenation

HR

:   hazard ratio

ICU

:   intensive care unit

PBW

:   predicted body weight

PEEP

:   positive end-expiratory pressure

SOFA

:   Sequential Organ Failure Assessment

VILI

:   ventilator-induced lung injury

LCC and KCK took responsibility for the accuracy of the data analysis and drafting manuscript. HCH, CYH, CHC performed study design and data acquisition. FCT and CTY were responsible for primary data analysis. CCH and HPW performed interpretation of the results. All authors read and approved the final manuscript.

Acknowledgements {#FPar1}
================

The authors would like to thank Chiu-Hua Wang and Shin-Wen Bai for data management and appreciate the patients and staff of ICUs at Chang Gung Memorial Hospital. We thank Mr. Yu-Jr Lin in Clinical Informatics and Medical Statistics Research Center, Chang Gung Memorial Hospital, for validating and confirming all the statistics in this study.

Competing interests {#FPar2}
===================

The authors declare that they have no competing interests.

Availability of data and materials {#FPar3}
==================================

The datasets supporting the conclusions of this article are included within the article.

Consent for publication {#FPar4}
=======================

Written informed consent was not obtained for publication of these data due to the retrospective nature of the study.

Ethics approval and consent to participate {#FPar5}
==========================================

The Institutional Review Board of Chang Gung Medical Foundation approved the retrospective clinical data collection (CGMH IRB No. 201600632B0), and no consents were required for this type of study.
